文献速递技术与安全心血管胸部PET

成纤维细胞活化蛋白PET:超越肿瘤的应用

Fibroblast Activation Protein-Directed PET: Expanding FAPI Beyond Cancer.
PubMed 文献 · AJR Am J Roentgenol · 2026-09-23

本文综述了成纤维细胞活化蛋白(FAP)靶向PET在非肿瘤疾病中的应用证据。FAP表达与病理性组织重塑、慢性炎症和纤维化密切相关,提示其可作为活动性组织重塑的影像生物标志物。目前证据多来自早期探索性研究,FAP靶向治疗在非肿瘤领域尚处于临床前阶段。

要点

  • FAP表达非肿瘤特异性,与纤维化、炎症及组织重塑相关
  • FAP PET在心脏、血管、风湿等多类非肿瘤疾病中显示潜力
  • 现有证据多为早期研究,需进一步验证后用于临床监测

核心结论

  • FAP靶向PET有潜力成为纤维化驱动性疾病监测中有价值的补充工具

研究设计与样本

  • 本研究为Special Series Review,综述FAP靶向PET在多种非肿瘤疾病中的早期证据
  • 涵盖心脏疾病(缺血性心脏病、非缺血性心肌病、瓣膜病变)、血管疾病(动脉粥样硬化、血管炎、动脉瘤)及风湿性疾病(间质性肺病、炎性关节炎、IgG4相关疾病)等领域

关键影像表现/征象

  • FAP表达由活化的成纤维细胞介导,与病理性组织重塑、慢性炎症和纤维化紧密相关

临床应用与阅片要点

  • FAP PET可能作为活动性组织重塑的影像生物标志物用于疾病监测

局限性

  • 支持性临床证据主要来自早期阶段研究,目前仍属于探索性阶段

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Fibroblast activation protein (FAP) has gained clinical interest as a target for imaging and therapy in a spectrum of oncologic diseases in recent years. Yet, FAP expression by activated fibroblasts is not specific to the tumor microenvironment but rather shows tight coupling to pathologic tissue remodeling, chronic inflammation, and fibrosis across a broad spectrum of nonmalignant diseases. This linkage provides a compelling biologic rationale for extending FAP-directed imaging beyond oncologic applications. Indeed, across various cardiac (ischemic heart disease, nonischemic cardiomyopathy, valvular pathology), vascular (atherosclerosis, vasculitis, aneurysm), rheumatologic (interstitial lung disease, inflammatory arthritis, IgG4-related disease), and other conditions, emerging data suggest that FAP-directed PET may serve as an imaging biomarker for active tissue remodeling. Nonetheless, the supporting clinical evidence is derived primarily from early-stage studies and remains largely exploratory at present. FAP-targeted therapies (e.g., FAP-targeting radiopharmaceutical therapies and chimeric antigen receptor T-cells) are also being actively explored outside of oncology in preclinical settings. While further investigation remains needed, FAP-directed PET has the potential to become a valuable addition to fibrosis-driven disease monitoring. Within this context, this Special Series Review highlights the current early evidence and future potential of FAP-directed PET across a variety of nononcologic conditions.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Enke, Barton, Kimura, et al. Fibroblast Activation Protein-Directed PET: Expanding FAPI Beyond Cancer. AJR Am J Roentgenol. 2026. PMID: 42776577. doi:10.2214/AJR.26.35590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。